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AbstrACt
Objective To assess the prevalence, trend and associated 
factors for immunological failure (IF), and the magnitude 
of antiretroviral therapy (ART) shift among adults infected 
with HIV in Southwest Ethiopia.
setting A retrospective cohort study was undertaken 
using the data from ART clinic at Jimma University 
Teaching Hospital from 21 June 2003 to 15 March 2015.
Participants Retrospective analysis of 4900 HIV-infected 
adult patient records dating from June 2003 to March 
2015 was conducted.
Primary outcome measure The primary outcome was 
IF defined when cluster for differentiation 4 (CD4) count 
falls to the baseline (or below) or persistent CD4 levels 
below 100 cells/mm3 after 6 months of ART treatment. The 
analyses included descriptive and inferential statistics.
results 546 (19.5%) adults had developed clinical 
failure (CF), 775 (19.7%) adults had developed IF and 
1231 (25.1%) had developed either CF or IF or both. The 
prevalence of IF was consistently high throughout the 
decade. Age 25 to ≤50 years adjusted OR (AOR 1.5, 9% CI 
1.2 to 2.4), being female (AOR 1.8, 95% CI 1.3 to 1.9), late 
presenter for HIV care (AOR 2.2, 95% CI 1.6 to 2.7) and 
having baseline CD4 count below 200 cells/mm3 (AOR 5.5, 
95% CI 4.1 to 7.4), and having no history of HIV testing 
before diagnosis (AOR 0.7, 95% CI 0.5 to 0.9) were the 
predictors for IF. Only 29 (0.9%) adults infected with HIV 
were shifted to second-line ART regimen.
Conclusions The magnitude of CF or IF or both was found 
significant and consistently high throughout the calendar 
year although ART shift was found minimal. HIV-infected 
adult patients with IF were early age adults, females, late 
presenters for HIV care, and those who had low baseline 
CD4 counts and history of HIV testing before diagnosis.
IntrOduCtIOn 
The advent of highly active antiretroviral 
therapy (ART) since 1996 has significantly 
reduced HIV-related diseases, improved 
quality of life of patients with HIV and 
decreased deaths associated with HIV.1 2 Even 
though the ART is scaled up worldwide, the 
coverage is still low. As of 2015, the majority 
of countries had low (<50%) ART coverage, 
few countries had moderate (50%–80%) 
and none had high (>80%) coverage.2 3 
The estimated global ART coverage in 2015 
was low (40.6%), of which North Africa and 
Middle East had the lowest coverage (19%) 
and high-income countries had the highest 
(67%).2 Sub-Saharan Africa (SSA) had also 
low ART coverage (42.35%) in 2015 and 
Ethiopia, one of the countries in SSA, had 
51.9% coverage.2 The impediments in the 
ART programmes are not limited to the issue 
of coverage. A substantial number of patients 
had developed immunological,4–7 clinical 
failure (CF)5 8 9 and/or treatment failure 
(TF).
Immunological failure (IF) was consid-
ered as a surrogate marker for virological 
failure.10 11 Thus, IF vividly influences the 
performance of a virological suppression 
goal of the UNAIDS (Joint United Nations 
Programme on HIV and AIDS) 90-90-90 
targets12 that aimed at achieving 90% of 
the virological success of patients on ART. 
Research has reported an IF magnitude of 
23%–33.1% in Europe,13 9%–18% in Asia14 15 
and 11%–39% in Africa.16 In Ethiopia, few 
studies have assessed IF4 6 7 17 and reported a 
prevalence of 6.8%–21%. The above studies 
presented the following risk factors, but 
not limited to: unemployment, low baseline 
cluster for differentiation 4 (CD4) cell, base-
line WHO clinical stage 4, poor adherence 
to treatment, not disclosing HIV status and 
strengths and limitations of this study
 ► The study included 12-year retrospective follow-up, 
and had involved large sample size bigger than sev-
eral other similar studies.
 ► The study assessed the outcomes of immunological 
failure, and this was not studied so far.
 ► The source of the data was a record based and 
could have incompleteness.
 ► The context of treatment failure attributed to immu-
nological and/or clinical failure could be a spuriously 
biased estimate.
 ► The findings may not infer to another level of 
health institutions such as health centres or private 
hospitals.
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development of new opportunistic infection (OI) after 
starting treatment.
However, all the studies that assessed the prevalence 
and risk factors of IF4 6 7 17 18 were conducted in the 
settings where the prevalence of HIV was below 2%. 
Jimma—the current study setting—is near Gambella 
region (Southwest Ethiopia), a region known to have the 
maximum prevalence rate (6.5%) of HIV in Ethiopia.19 
The hospital serves both Jimma and Gambella zones. 
Since the prevalence of HIV in Southwestern region is 
higher (6.5%) than other parts of the nation (<2%), it 
is essential to comprehend whether the high prevalence 
is linked with other factors than the ones reported in 
similar studies in Ethiopia. In addition, unlike the rest 
of Ethiopia, the Southwest region is composed of diverse 
population groups. A substantial number of HIV-infected 
patients enrolled in the ART clinic in Jimma University 
Teaching Hospital (JUTH) come from a refugee camp 
situated near Jimma, which hosts refugees from different 
East African countries.
The exposure of ART—if not taken according to the 
recommendations—leads to drug resistance and subse-
quent clinical and/or IF. Therefore, timely switching to 
alternatives (second-line or third-line drugs) is immensely 
needed.20 Late shifting of regimens further increases the 
risk of viral resistance and endangers the long-term prog-
nosis.20 ART switch is less common in under-resourced 
settings than in resourced countries.21 In Ethiopia, the 
magnitude of shifting to second-line ART drugs due to 
TF attributed to IF and/or CF has not been assessed. 
Furthermore, the trend and outcomes across the immu-
nological status of HIV-infected adults in Ethiopia is yet to 
be addressed. Hence, it is crucial to explore IF contextu-
ally. The performance assessment of virological suppres-
sion of the UNAIDS 90-90-90 treatment targets was also 
never assessed in the nation. We performed a historical 
data analysis to assess the prevalence, trend, outcomes 
and associated factors of IF, and the magnitude of shifting 
to second-line ART drugs among adults in Southwest 
Ethiopia.
MethOds
study design, setting and participants
A retrospective cohort study was carried out using data 
from 21 June 2003 to 15 March 2015 from the ART 
clinic at JUTH. We have described the study setting else-
where.22 23 The target population included all HIV-in-
fected adult patients age ≥15 years enrolled in ART care at 
JUTH in Southwest Ethiopia. Patients should be followed 
for at least 6 months after ART initiation. If the CD4 level 
or WHO clinical stage of the patients was not recorded, at 
least, at two points—beginning and after 6 months of ART 
initiation—records would be excluded from the analysis. 
Baseline refers the time when ART was started for the first 
time.
data source and procedures
Data were extracted from JUTH electronic medical 
records (EMRs) system called comprehensive care centre 
patient application database (C-PAD). This system was 
designed in 2007, and data recorded before 2007 were 
retrospectively copied from the paper in to the EMR 
system. In 2003–2015, 4900 adults were on ART out of 
8172 HIV-infected patients in the care, and 3939 (81%) 
of them were included in the analysis for IF (figure 1). 
Health workers record the clinical and non-clinical char-
acteristics of the patients on a paper followed by entering 
into the EMR by data clerks. To ensure completeness, 
reliability and validity of the information, two data clerks 
enter the data. In addition, International Center for 
AIDS Care and Support at Colombia University assists the 
patient-level data management system.
study variables and measurements
WHO24 has set definitions for IF, CF and TF. The response 
variable was IF and dichotomised as yes and no. IF (yes) 
was defined if CD4 count of the HIV-infected adults falls 
to the baseline (or below) or persistent CD4 levels below 
100 cells/mm3 after 6 months of ART treatment.24 The 
independent variables included age, sex, marital status, 
educational status, religion, ART adherence, cotrimox-
azole adherence, baseline WHO clinical staging, baseline 
CD4 count, late presentation for HIV care, tubercu-
losis (TB)/HIV coinfection, baseline functional status, 
history of HIV testing before diagnosis and ART shift. CF 
was defined when new or recurrent clinical conditions 
denoting WHO clinical stage 4 6 months after an effec-
tive treatment.24 TF refers to a combination of CF and IF. 
ART discontinuation was either loss to follow-up (LTFU), 
defaulting and/or stopping medication while remaining 
in care. LTFU was defined when patients had been on 
ART treatment and missed at least three clinical appoint-
ments but not yet been classified as ‘dead’ or ‘transferred 
out’ (TO). Defaulting was defined when patients had 
been on ART treatment and missed less than three clin-
ical appointments but not yet been classified as ‘dead’ 
or ‘TO’. In addition, stopping medication was defined 
when patients had stopped treatment due to any reason 
while they have remained in care. TO is the official trans-
ferring of the patient to another ART clinic. Functional 
status was categorised in to work (able to perform usual 
work), ambulatory (able to perform activity of daily 
living) and bedridden (not able to perform activity of 
daily living). ART switching is a change from first-line to 
second-line ART drugs. History of HIV testing refers to 
testing (one or more times) for HIV before diagnosis. 
Table 1 demonstrates the measurements of late presen-
tation for HIV care and level of adherence. If poor HIV 
outcomes such as IF, CF and TF were occurred more than 
once, the latest outcome was considered for analysis. The 
assessment for other outcomes such as discontinuation, 
adherence and ART shift was conducted at the end of 
follow-up time.
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statistical analyses
We undertook the analysis of descriptive and inferential 
statistics. Descriptive statistics included frequency tables 
and proportions for categorical data, and median, range 
and line graph for continuous data. The 10-year trends 
for IF (data for years 2003 and 2015 were excluded since 
the number of months was incomplete) was described 
by line graph using a cumulative frequency percentage. 
The cumulative frequency percentage or proportion of 
patients with IF, denoted in Y-axis in figure 2, is calcu-
lated using the cumulative number of patients with 
IF (cumulative frequency for numerator) and eligible 
cumulative number of patients for IF (cumulative 
frequency for denominator) for each calendar year. 
Binary logistic regression was applied to assess factors 
associated with IF. Bivariate logistic regression analysis 
was performed to select the candidate variables to 
multiple logistic regression, and variables with p<0.25 
were included as candidate variables to multivariable 
logistic regression. P≤0.05 was considered a criterion for 
statistical significance in the final model. We performed 
multiple imputations (MIs) (n=5) assuming missing at 
random (MAR) pattern25 to treat missing data, and we 
reported a model with pooled imputed values.26 We 
used Hosmer and Lemeshow test to check goodness of 
fit of the final model. We summarised the data using OR 
and 95% CI. We used SPSS V.22.0 for all data analyses.
Patient and public involvement
We did not involve patients and public in the study—we 
simply extracted data from records.
Figure 1 Immunological status and their outcomes of HIV-infected adults in Jimma University Teaching Hospital in Southwest 
Ethiopia, 2003–2015. This figure presents the flow chart of immunological status and their outcomes of HIV-infected adults. 
ART, antiretroviral therapy; CD4, cluster for differentiation 4.  on 24 O
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results
description of study participants
In total, 8172 patients were enrolled in HIV care 
programme from 21 June 2003 to 15 March 2015 of whom 
4900 adult patients had been documented commence-
ment of ART (figure 1). demonstrates the characteristics 
of adult patients with HIV on ART. Of 4900 HIV-infected 
patients on ART, four out of five were aged 25–50 years, 
three out of five were females, one out of two were 
married, two out of three were Christians and two out 
of five completed primary education. The median CD4 
count was 156 (0–1313) cells/mm3, and more than half 
(54.3%) of the participants had baseline WHO clinical 
stage 3 or 4. The magnitude of TB/HIV coinfection over 
the study period was 27.9%. The median time on ART 
was 49 months, and the estimated survival time was 121.9 
(120.3–123.5) months.
IF, CF and Art regimen switching
Of the 4900 patients enrolled on ART in 2003–2015, 217 
patients were on ART for below 6 months, and baseline 
and 6 months CD4 level of 744 patients was not recorded. 
In total, 775 out of the 3939 patients (19.7%) had devel-
oped IF. Out of the patients with IF, 83 (10.7%), 88 
(11.3%) and 604 (77.9%) patients, respectively, were 
followed for 6 to ≤12, 12 to ≤24 and ≥24 months. Among 
the patients who developed IF, 33 (4.3%) patients had 
died, 101 (13%) patients had discontinued, 118 (15.2%) 
patients had TO and 516 (66.6%) were alive and on ART 
(figure 1). The magnitude of IF was steadily high since 
2008 and reached a peak in 2009 accounting for 24% 
followed by 21% in 2014. Figure 2 shows the trend in IF in 
HIV-infected patients on ART. In addition, 2807 patients 
were eligible for CF of whom 546 (19.5%) had developed 
the CF. A total of 1231 out of 4470 had developed either 
CF or IF or both—82 patients had both CF and TF. Twen-
ty-nine (0.9%) patients were shifted to second-line ART 
drugs.
Factors associated with IF among adult patients with hIV
Table 3 demonstrates the outputs from the multivariable 
logistic regression analysis of factors for IF obtained from 
the analysis of a complete case and MIs. Age between 25 
and ≤50 years, being female, late presenter for HIV care 
and having a baseline CD4 count below 200 cells/mm3 
were factors for IF, and having no history of HIV testing 
before diagnosis was a protective factor against IF. HIV-in-
fected adults age 25 to ≤50 years were 50% adjusted OR 
(AOR 1.5, 9% CI 1.2 to 2.4) more likely to develop IF than 
those aged 15 to ≤25 years. Females were 80% more likely 
than males (AOR 1.8, 95% CI 1.3 to 1.9) to develop IF. 
Patients who presented late for HIV care had double the 
risk of IF than early presenters (AOR 2.2, 95% CI 1.6 to 
2.7). In addition, patients with baseline CD4 count below 
200 cells/mm3 had nearly six times higher risk for IF than 
those with ≥200 cells/mm3 (AOR 5.5, 95% CI 4.1 to 7.4). 
Patients who had no history of HIV testing before diag-
nosis were 30% less likely (AOR 0.7, 95% CI 0.5 to 0.9) 
to develop IF as compared with those who had previous 
record of HIV testing.
Multiple imputations
The MIs analysis result (table 3) revealed that except for 
baseline CD4 count, all statistically significant variables in 
the complete case analysis were also reported to have a 
statically significant difference in the MIs analysis. TB/
HIV coinfection, a variable that was not statistically signif-
icant in the complete case analysis, was found to be a 
Table 1 Measurements for late presentation for HIV care and ART adherence, 2016
Late presentation for HIV care*53
Enrolled in 2003–2011 Enrolled in 2012–2015
CD4 lymphocyte count of <200 cells/µL irrespective of WHO 
clinical stage at the time of first presentation to the HIV care.
CD4 lymphocyte count of <350 cells/µL irrespective of WHO 
clinical stage at the time of first presentation to the HIV care.
WHO clinical stage 3 or 4 irrespective of CD4 count at the time 
of first presentation to the HIV care.†
WHO clinical stage 3 or 4 irrespective of CD4 count at the time 
of first presentation to the HIV care.†
Level of adherence‡54
Status Percentage of prescribed ART intake No of missing doses out of 30 No of missing doses out of 60
Good ≥95% <3 <4
Fair 85%–95% 3–5 4–9
Poor <85 ≥6 ≥9
*The definition for late presentation for HIV care among TB/HIV-coinfected population was only based on the CD4 criteria.22
†WHO clinical stage 3 was defined if one of the following is present in an HIV-diagnosed patient: weight loss of >10% body weight, 
chronic diarrhoea for >1 month, fever for >1 month, oral candidiasis, oral hairy leukoplakia or pulmonary TB within the previous year or 
severe bacterial infections; WHO clinical stage 4 was defined if one of the following is present in an HIV-diagnosed patient: HIV wasting 
syndrome, PCP (Pneumocystis carinii pneumonia), toxoplasmosis of the brain, cryptosporidiosis or isosporiasis with diarrhoea for 
>1 month, cytomegalovirus disease of an organ other than liver, spleen or lymph node, herpes simplex virus infection, progressive multifocal 
leucoencephalopathy, candidiasis, extrapulmonary TB, lymphoma, Kaposi’s sarcoma, HIV encephalopathy.
‡Clinicians and pharmacists ask patients and check the pill container to collect the number of missing doses or day.
ART/ARV, antiretroviral therapy; CD4, cluster for differentiation 4; TB, tuberculosis.
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statistically significant in MIs analysis in which patients 
with TB/HIV-coinfection had a greater risk of developing 
IF than patients with HIV alone.
dIsCussIOn
The current study was undertaken to assess IF in (and near) 
high HIV epidemic area and revealed a prevalence rate of 
19.7% with a sharp trend increase in the recent times. This 
prevalence is similar to a finding from a study conducted 
by Melsew Yayehird et al4 but is higher than the findings of 
studies conducted in the other part of the nation that was 
reported to be between 6.7% and 17.6%.6 7 17
The result shows that the prevalence rate of IF is signif-
icant particularly when compared with the other part of 
the nation. Thus, we can hypothesise that patients who 
come from high HIV-prevalence areas or attending their 
HIV care services near to high HIV-endemic settings has 
higher IF than patients who are attending their care in 
or near to low HIV-prevalence settings. The following 
explanations could partly justify the difference: (1) the 
presence of variety HIV-1 strains among people living 
with HIV in HIV prevalent areas is very high and this 
could challenge the immunological response benefited 
from the treatment27 28; (2) ART drug resistance is higher 
in high than low HIV-prevalence settings, and the drug 
resistance diminishes the immunological benefit of the 
treatment29 and (3) HIV-infected people who come 
from high HIV-prevalence settings have less access to 
health services, lower economic status and lower HIV 
care-related knowledge30 and this could negatively influ-
ence the immunological benefit of ART. For instance, 
Table 2 Characteristics of adult HIV-infected patients 
enrolled on ART care in Southwest Ethiopia from 2003 to 
2015, Jimma, Ethiopia
Variable n=4900, n (%)
Age in years 
  15 to ≤25 711 (14.5)
  25 to ≤50 3937 (80.3)
  50+ 252 (5.2)
  Median (range) age in years 30 (15–81)
ART follow-up time in months, 
median (range)
49 (0–137)
Estimated survival time in months, 
median (95% CI)
121.9 (120.3 to 123.5)
Sex 
  Male 1971 (40.2)
  Female 2929 (59.8)
Marital status*
  Never married 897 (20.9)
  Married 2094 (48.7)
  Separated/divorced/widowed 1311 (30.5)
Education*
  No education 945 (21.9)
  Primary 1687 (39.1)
  Secondary and above 1685 (39)
Religion*
  Muslim 1402 (32.6)
  Christian† 2893 (67.4)
Baseline WHO classification*
  1 or 2 1355 (45.7)
  3 or 4 1608 (54.3)
Baseline CD4 count (cells/mm3)*
  <200 3275 (73.6)
  ≥200 1174 (26.4)
  Median (range) 156 (0–1313)
Hx of TB/HIV coinfection*
  No 3533 (72.1)
  Yes 1367 (27.9)
ARV adherence*
  Good 4064 (82.9)
  Fair or poor 836 (17.1)
Cotrimoxazole adherence*
  Good 4119 (94.4)
  Fair or poor 762 (15.6)
Hx of HIV testing*
  Yes 2860 (58.4)
  No 2040 (41.6)
ART shift*
  No 3190 (99.1)
  Yes 29 (0.9)
Continued
Variable n=4900, n (%)
Baseline functional status*
  Work or ambulatory 3064 (68.1)
  Bedridden 1437 (31.9)
Timing to HIV diagnosis 
  Early 894 (33.3)
  Late 1788 (66.7)
Clinical failure*
  No 2261 (80.5)
  Yes 546 (19.5)
Immunological failure*
  No 3164 (80.3)
  Yes 775 (19.7)
Treatment failure*
  No 3239 (72.5)
  Yes 1231 (27.5)
*Only valid percentage is calculated.
†Orthodox, catholic, protestant.
ART/ARV, antiretroviral therapy; CD4, cluster for differentiation 
4; TB, tuberculosis.
Table 2 Continued 
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the 2016 Ethiopian Demographic Health Survey (31 
stated that two-thirds (66%) of Tigray (a regional state 
located in Northern Ethiopia) women versus less than 
half (43.9%) of Gambella (a regional state located in 
Southwest Ethiopia) women stated that HIV can be 
prevented by using condoms and limiting sexual inter-
course to one uninfected partner. Similarly, this survey 
described that more than three-fourths (84.2%) of 
Tigray men versus two-thirds (69.2%) of Gambella men 
stated that HIV can be prevented by using condoms and 
limiting sexual intercourse to one uninfected partner. 
Therefore, intensive effort has to be done to reduce the 
IF and subsequently a virological failure.
In the current study, most patients (78%) with IF 
were followed in ART care for ≥2 years. This shows that 
the prevalence of IF grows when the follow-up time 
increases, and this was similar to the previous studies 
conducted elsewhere.4 8 The relationship between 
longer duration of treatment and IF could be justified 
by multiple explanations, and needs further study. But 
it may be partly justified by the frequent (and inappro-
priate) change in dose or types of ART, non-adherence 
when patients are on ART for long periods and ART 
resistance.8 9 Thus, long-term retention requires serious 
attention. Plasma HIV-1 RNA is not available for routine 
viral load monitoring in resource-limited countries 
such as Ethiopia.18 Hence, WHO32 and several other 
studies10 11 33 recommended immunological success as a 
surrogate marker for the virological suppression. In the 
current study, 19.7% of patients had IF; said in another 
way, 80.3% of patients had immunological success. This 
80% (even lower) performance of virological suppres-
sion is less than the current goal of virological suppress 
of the UNAIDS 90-90-90 target that aimed 90% viral 
suppression for those on treatment.12 Nevertheless, as 
the predictive accuracy is low, immunological success 
overestimates virological suppression.34 35 Therefore, 
plasma HIV viral load testing should be accessible to 
regularly monitor the patients. The use of GenXpert 
for HIV viral load testing36 is also another option for 
resource-limited countries.
HIV-infected patients with IF were more likely to 
be between 25 and ≤50 years of age, females, late 
presenters for HIV care, and those who had low base-
line CD4 counts and history of HIV testing before 
diagnosis. Age was reported to have a significant influ-
ence on probability of IF. In fact, other literatures37 38 
reported that older adults are more likely to develop 
IF than younger group. The impairment in immune 
recovery due to age-related reduction in thymic func-
tion and other regenerative mechanisms could justify 
the link between older adults and IF.38 Older adults are 
also highly likely to be diagnosed late with HIV than the 
younger ones,39 a phenomenon that prevents an immu-
nological benefit from ART.40 Even though, majority 
of the literatures41–43 reported no statistical difference 
between sex and IF, the proportion in the current study 
and one other study16 revealed that females were more 
likely to develop IF than males. In the present study, 
females were the majority of the study participants. This 
shows that females are still the vulnerable groups, and 
are at a greater risk of negative HIV care outcomes. 
This could be attributed to high levels of stigma,44 45 low 
literacy status46 and use of traditional medicine.47 Thus, 
attention has to be given for females in each series of 
the cascade of care.
Similar to findings from other studies,16 48 low base-
line CD4 counts were linked with IF. Furthermore, late 
presenters for HIV care had a greater risk of IF than early 
presenters, and this finding was supported by findings 
from studies conducted in SSA.49 50 Research has shown 
that delayed presenter and patients with low baseline 
Figure 2 Trends in the percentage distribution of IF in HIV-infected adults on ART, Southwest Ethiopia, 2004–2014. This figure 
presents the trend of IF. Y-axis shows the cumulative frequency percentage of patients with IF for each calendar year. ART, 
antiretroviral therapy; IF, immunological failure.
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  15 to ≤25 488 (15.4) 74 (9.5) 1 1 1
  25 to ≤50 2560 (80.9) 674 (87) 1.7 (1.3 to 2.3)* 1.5 (1.2 to 2.4)* 1.8 (1.7 to 2.1)*
  50+ 116 (3.7) 27 (3.5) 1.5 (0.9 to 2.5) 1.3 (0.7 to 2.9) 2.3 (1.9 to 2.7)*
Sex 
  Male 1488 (47) 274 (35.4) 1 1 1
  Female 1676 (53) 501 (64.6) 1.6 (1.4 to 1.9)* 1.8 (1.3 to 1.9)* 1.7 (1.6 to 1.8)*
Marital status 
  Never married 632 (23.3) 152 (21.7) 1 1
  Married 1316 (48.5) 357 (51.1) 1.1 (0.9 to 1.4) 1.04 (0.0 to 1.1)
  Separated/divorced/
  widowed
766 (28.2) 190 (27.2) 1.03 (0.8 to 1.3) 1.9 (0.7 to 2.1)
Educational status 
  No education 559 (20.5) 145 (20.8) 1 1 1
  Primary 1089 (39.9) 287 (41.1) 1.01 (0.8 to 1.3) 1.3 (0.7 to 2.9) 1.03 (0.9 to 1.1)
  Secondary and above 1084 (39.7) 266 (38.1) 0.9 (0.8 to 1.2) 0.7 (0.4 to 3.7) 0.9 (0.8 to 1.1)
Religion 
  Muslim 871 (32) 239 (34.5) 1 1
  Christian‡ 1849 (68) 453 (65.5) 0.9 (0.8 to 1.06) 0.8 (0.7 to 1.9)
Baseline WHO status 
  Stage 1 or 2 842 (45.1) 216 (46.6) 1 1
  Stage 3 or 4 1027 (54.9) 248 (53.4) 0.9 (0.8 to 1.2) 1.7 (0.8 to 3.9)
Baseline CD4 
  ≥200 cells/μL 2558 (80.8) 350 (45.2) 1 1 1
  <200 cells/μL 606 (19.2) 425 (54.8) 5.1 (4.3 to 6.06)* 5.5 (4.1 to 7.4)* 1.8 (0.9 to 3.01)
Clinical failure 
  No 1493 (81.3) 352 (80.5) 1 1 1
  Yes 343 (18.7) 85 (19.5) 1.1 (0.8 to 1.4) 1.3 (0.9 to 1.8) 2.8 (0.7 to 4.9)
HIV care presentation 
  Early 682 (36.5) 99 (21.3) 1 1 1
  Late 1187 (63.5) 365 (78.7) 2.1 (1.7 to 2.7)* 2.2 (1.6 to 2.7)* 1.1 (1.01 to 1.2)*
Hx of TB/HIV coinfection 
  No 2229 (70.4) 536 (69.2) 1 1 1
  Yes 935 (29.6) 239 (30.8) 1.06 (0.9 to 1.3) 1.8 (0.7 to 4.9) 1.08 (1.01 to 1.2)*
ART adherence 
  Good 2595 (82) 648 (83.6) 1 1
  Fair or poor 569 (18) 127 (16.4) 0.9 (0.7 to 1.1) 0.9 (0.8 to 1.9)
Cotrimoxazole adherence 
  Good 2632 (83.5) 639 (82.5) 1
  Fair or poor 521 (16.5) 136 (17.5) 0.9 (0.8 to 1.2)
Baseline functional status 
  Working or ambulatory 1992 (68.1) 549 (74.7) 1 1
  Bedridden 933 (31.9) 186 (25.3) 0.7 (0.6 to 0.9)* 0.8 (0.6 to 1.02)
Hx of HIV testing 
  Yes 1793 (56.7) 468 (60.4) 1 1 1
  No 1371 (43.3) 307 (39.6) 0.9 (0.7 to 1.0) 0.7 (0.5 to 0.9)* 0.8 (0.7 to 0.9)*
Continued
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CD4 counts are at an elevated risk for OIs and multiple 
comorbidities.51 This prevents patients from taking the 
treatment consistently and gaining the immunological 
benefit.40 Frequent screening and opt-out testing would 
normalise HIV testing, reduce stigma associated with 
HIV care and help those infected with HIV find out 
earlier.52
Finally, people who had history of HIV testing before 
diagnosis were less likely to gain an immunological 
response compared with those who had not. This might 
be justified by the fact that those who had history of 
HIV testing before diagnosis and once got HIV-nega-
tive result might feel sense of well-being and get tested 
late. Thus, the delayed HIV diagnosis and then delayed 
presentation to ART care could challenge the immuno-
logical gain from ART.40 However, it is interesting that 
ART adherence was not statistically associated with IF, 
and this needs further research. Out of the 775 patients 
who developed IF or 546 patients who developed CF, 
only 29 adults switched to second-line ART drugs. This 
shows that the great majority of patients diagnosed with 
TF attributing to IF and/or CF were not moved onto 
second-line therapy.
The study has some limitations: (1) the retrospective 
nature of the study does not assure the cause–effect 
relationship as some of the variables could be measured 
after the occurrence of the outcome; (2) the possibility 
of having incomplete information could reduce the 
precision of estimates for the included variables; none-
theless, we have addressed this using MIs; (3) the source 
of information—being from public referral hospital—
may not infer to another level of health institutions 
such as health centres or private hospitals; (4) the lack 
of viral load to detect TF is another limitation and (5) 
while including the latest episode of a poor outcome 
in an analysis of predictors, factors associated with first 
poor outcome may be different from factors associated 
to a poor outcome in a person who has already been on 
ART for several years and experienced multiple previous 
poor outcomes. Furthermore, we are unable to extract 
some data prior to each episode of IF to conduct further 
analyses, and explicitly identify associated factors for 
each episode.
COnClusIOns
In conclusion, the 19.7% prevalence of IF is higher 
in or near high HIV-prevalence settings—the current 
study setting—than low HIV-prevalence settings in Ethi-
opia that reported an IF prevalence of 6.7%–17.6%. 
However, great majority of the associated factors from 
the current study are incongruent to the findings of 
previous studies conducted in the country and else-
where. Patients with IF were more likely to be early age 
adults, females, late presenters for HIV care, and have 
a low (<200 cells/mm3) baseline CD4 count and history 
of HIV testing before diagnosis. Very few patients were 
shifted to second-line ART drugs despite the high preva-
lence of CF and/or IF. Research has shown that delayed 
ART regimen switching increases the risk of viral resis-
tance and endangers the long-term prognosis of HIV-in-
fected patients on ART. Hence, to further improve 
immunological response of the patients, benchmarking 
practices and effective programmes should be devel-
oped to diagnose and link HIV-infected patients timely, 
improve retention care and increase the regular immu-
nological and virological monitoring of the patients.
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  No 2086 (98.9) 500 (99.2) 1 1
  Yes 24 (1.1) 4 (0.8) 0.7 (0.2 to 2.01) 0.8 (0.6 to 1.03)
*Statistically significant at p≤0.05.
†Only valid percentage is considered. 
‡Orthodox, protestant or catholic.
AOR, adjusted OR; ART, antiretroviral therapy; CD4, cluster for differentiation 4; COR, crude OR; IF, immunological failure; TB, tuberculosis.
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